Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Inclusion Criteria:

• Have metastatic urothelial carcinoma (UC) or other solid tumor with a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration.
• Have exhausted other approved treatments, including erdafitinib for UC.
• Are not eligible for an ongoing vepugratinib clinical trial

Exclusion Criteria:

• Currently enrolled in an ongoing clinical study of vepugratinib
• Have a known severe (greater than or equal to (≥) Grade 3) hypersensitivity to any component or excipient of vepugratinib.
• Current evidence of corneal keratopathy or retinal disorder confirmed by ocular examination. Exception: Individuals with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk.
• Significant cardiovascular disease:
• Are pregnant, breastfeeding, or intent to become pregnant during the study or within 6 months of the last dose of study intervention.